Alert detail
FDA Approval: ROMVIMZA (VIMSELTINIB) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA219304Specialty: OncologyAdded: 7/1/2026Effective: February 14, 2025federal register
What changed
Oral kinase inhibitor Romvimza routes to Part D; no J-code expected.
Who’s affected: Oncology billing teams · Effective: February 14, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.